Mayo Clinic Doctor Says Mark Cuban’s Cost Plus Drugs is Bringing “Access” to U.S. Healthcare


Mark Cuban’s Cost Plus Drugs is making waves in the pharmacy market, gaining more than 1.2 million customers and selling over 1000 generic low-cost drugs at a fraction of the prescription price that Big Pharma puts on the marketplace. The big question now is whether the supply chain can fundamentally shift toward Cuban’s low-cost model as brand-name drugs resist the shift. Assistant Professor of Epidemiology for the Mayo Clinic College of Medicine at Mayo Clinic, Dr. Jose Medina-Inojosa, breaks down the ripple effects from the Cost Plus Drugs approach to drug product logistics.

Dr. Medina-Inojosa’s Thoughts

“Just to give you a little of context, as we all know, we are probably working in the best healthcare system of the world, but one of the major challenges that we have is access, and specifically prescription access is becoming a major problem in the United States. About 18 million people, about 7% of the whole United States, have a lot of trouble accessing medications and this company is probably gonna help some of the problems. They’re based in Dallas, they’re expanding access, they’re negotiating new deals with drug companies, getting access to generic medications that are about 85% cheaper. Talking about, to give you some example for some leukemia medications, it could take a drug from $2,500 to $14 at Mark Cuban’s Cost Plus Drugs, which is extremely exciting.

They’re also working with manufacturing their ordinary prescription medications in Dallas, and I think down the line they’re promising to continue to expand their deals and their reach over the next six or 12 months. So it’s not the major solution to fix all the problems, but I think it’s a really good step in the right direction. And I’m looking forward to see how it will help shape the face of healthcare and how it will help deliver access.”

Follow us on social media for the latest updates in B2B!


Hotel demand
Travel in 2023 Isn’t Slowing: Will Economic Headwinds Threaten Hotel Profits?
December 1, 2022

Travel in 2023 will not be slowing down. This would normally be perceived as good news for hoteliers, but PwC’s Hospitality Directions report paints a more mixed picture for hotels; the report indicates that economic headwinds may threaten the pace of recovery in the industry, despite record highs for metrics like RevPAR this year. According […]

Read More
B2B payments
There Will Not Be a Dominant Player Taking Over B2B Payments in 2023
December 1, 2022

B2B payments are facing an exciting trend in the space, as vendors continue to innovate to offer new and better solutions for this $30 trillion industry. According to PaymentsJournal, continuous improvements in B2B payments are largely driven by the complicated infrastructures necessary for international payments and a pressing need for greater flexibility. With a company […]

Read More
COP27 drew focused attention on the role of the built environment in global carbon emissions. Where does AEC need to start to make a change?
Is the COP27 Focus on AEC Carbon Emissions Telling the Whole Story?
December 1, 2022

Construction sustainability continues to be an emphasis for international leaders. COP27, the UN’s gathering of more than 90 heads of state and 35,000 delegates from 190 countries, convened earlier in early November to discuss unified action against climate change and which industries need to take on a bulk of the responsibility to adjust operations and […]

Read More